545 related articles for article (PubMed ID: 32962718)
21. Docetaxel-Based Neoadjuvant Chemotherapy Followed by En Bloc Resection for Esophageal Adenocarcinoma: A 15-Year Retrospective Analysis from a Regional Upper Gastrointestinal Cancer Network.
Tankel J; Ahmed N; Mueller C; Najmeh S; Spicer J; Mulder D; Cool-Lartigue J; Rousseau M; Frechette D; Sud S; Kavan P; Moghrabi A; Champagne M; Lemay F; Dalfen R; Sirhan S; Asselah J; Alcindor T; Ferri L
Ann Surg Oncol; 2024 Apr; 31(4):2461-2469. PubMed ID: 38142255
[TBL] [Abstract][Full Text] [Related]
22. Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Shiraishi O; Kato H; Momose K; Hiraki Y; Yasuda A; Shinkai M; Imano M; Yasuda T
Oncology; 2023; 101(3):203-212. PubMed ID: 36599320
[TBL] [Abstract][Full Text] [Related]
23. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
[TBL] [Abstract][Full Text] [Related]
24. Safety of thoracoscopic esophagectomy after induction chemotherapy for locally advanced unresectable esophageal squamous cell carcinoma.
Akiyama Y; Iwaya T; Endo F; Nikai H; Baba S; Chiba T; Kimura T; Takahara T; Otsuka K; Nitta H; Mizuno M; Kimura Y; Koeda K; Sasaki A
Asian J Endosc Surg; 2020 Apr; 13(2):152-159. PubMed ID: 31313511
[TBL] [Abstract][Full Text] [Related]
25. Tumor-infiltrating lymphocytes in patients undergoing esophagectomy following neoadjuvant DCF therapy.
Takahashi K; Sakashita Y; Murahashi M; Kubota H; Shimoda M; Ishikawa Y; Tanishima Y; Kurogochi T; Yano F; Eto K
J Surg Oncol; 2024 Mar; 129(4):700-707. PubMed ID: 38031881
[TBL] [Abstract][Full Text] [Related]
26. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.
Kim S; François E; André T; Samalin E; Jary M; El Hajbi F; Baba-Hamed N; Pernot S; Kaminsky MC; Bouché O; Desrame J; Zoubir M; Ghiringhelli F; Parzy A; De La Fouchardiere C; Smith D; Deberne M; Spehner L; Badet N; Adotevi O; Anota A; Meurisse A; Vernerey D; Taieb J; Vendrely V; Buecher B; Borg C
Lancet Oncol; 2018 Aug; 19(8):1094-1106. PubMed ID: 30042063
[TBL] [Abstract][Full Text] [Related]
27. Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy.
Xi M; Zhang P; Zhang L; Yang YD; Liu SL; Li Y; Fu JH; Liu MZ
Jpn J Clin Oncol; 2017 Aug; 47(8):683-689. PubMed ID: 28453815
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
[TBL] [Abstract][Full Text] [Related]
29. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
[TBL] [Abstract][Full Text] [Related]
30. Tumor/normal esophagus ratio in (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for response and prognosis stratification after neoadjuvant chemotherapy for esophageal squamous cell carcinoma.
Izumi D; Yoshida N; Watanabe M; Shiraishi S; Ishimoto T; Kosumi K; Tokunaga R; Taki K; Higashi T; Harada K; Miyata T; Ida S; Imamura Y; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yamashita Y; Baba H
J Gastroenterol; 2016 Aug; 51(8):788-95. PubMed ID: 26671045
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
32. Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
Pennathur A; Luketich JD; Landreneau RJ; Ward J; Christie NA; Gibson MK; Schuchert M; Cooper K; Land SR; Belani CP
Ann Thorac Surg; 2008 Jun; 85(6):1930-6; discussion 1936-7. PubMed ID: 18498797
[TBL] [Abstract][Full Text] [Related]
33. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Makiuchi T; Nagumo R; Kitagawa Y
Ann Surg Oncol; 2020 Feb; 27(2):460-467. PubMed ID: 31376034
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic strategy aiming at R0 resection for borderline-resectable esophageal squamous cell carcinoma using induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil.
Nakajima M; Muroi H; Kikuchi M; Kubo T; Inoue N; Ihara K; Nakagawa M; Morita S; Nakamura T; Kojima K
Gen Thorac Cardiovasc Surg; 2023 Oct; 71(10):584-590. PubMed ID: 37060435
[TBL] [Abstract][Full Text] [Related]
35. Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial.
Shiraishi O; Makino T; Yamasaki M; Tanaka K; Yamashita K; Ishida T; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Doki Y; Yasuda T
Esophagus; 2021 Oct; 18(4):825-834. PubMed ID: 33738656
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma.
Fan Y; Jiang Y; Zhou X; Chen Q; Huang Z; Xu Y; Gong L; Yu H; Yang H; Liu J; Lei T; Zhao Q; Mao W
Oncotarget; 2016 Aug; 7(31):50624-50634. PubMed ID: 27244882
[TBL] [Abstract][Full Text] [Related]
38. Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.
Tryakin A; Pokataev I; Kononets P; Fedyanin M; Bokhyan V; Malikhova O; Minin K; Shogenov M; Stilidi I; Vybarava A; Davydov M; Tjulandin S
Jpn J Clin Oncol; 2016 Jul; 46(7):610-4. PubMed ID: 27052115
[TBL] [Abstract][Full Text] [Related]
39. Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer.
Hashimoto M; Shirakawa Y; Maeda N; Tanabe S; Noma K; Sakurama K; Katsui K; Nishizaki M; Fujiwara T
Esophagus; 2020 Apr; 17(2):127-134. PubMed ID: 31897761
[TBL] [Abstract][Full Text] [Related]
40. Significance of chemotherapy-free interval and tumor regression grade in patients with recurrent esophageal squamous cell carcinoma receiving chemotherapy with fluorouracil and platinum after esophagectomy following preoperative chemotherapy.
Okunaka M; Kotani D; Demachi K; Fujiwara H; Sakashita S; Yoshino T; Fujita T; Kojima T
Esophagus; 2022 Apr; 19(2):240-249. PubMed ID: 34611830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
